IDEXX Laboratories (IDXX) 10-K Summary — Year Ended Dec 31, 2024
This filing is a 10-K annual report for IDEXX Laboratories, Inc. The supplied data includes financial metrics for the fiscal year but lacks detailed business descriptions, risk factors, and liquidity discussion.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
This filing is a 10-K annual report for IDEXX Laboratories, Inc. The supplied data includes financial metrics for the fiscal year but lacks detailed business descriptions, risk factors, and liquidity discussion.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$3.9B
Revenue reported for the fiscal year.
Operating income
$1.1B
Income from operations reported for the year.
Net income
$887.9M
Net income reported for the year.
Operating cash flow
$929M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $3.2B | n/a |
| Dec 31, 2022 | $3.4B | +4.7% |
| Dec 31, 2023 | $3.7B | +8.7% |
| Dec 31, 2024 | $3.9B | +6.5% |
Business overview
The business overview section is not provided in the supplied filing context. No description of the company's operations, products, or markets is available.
Financial performance
Revenue increased compared to the prior year, continuing a trend of positive growth over recent periods. The company also reported operating income, net income, and operating cash flow for the fiscal year.
Material risks
The filing does not contain specific risk factor descriptions. No material risks are stated in the supplied context.
Liquidity and capital
Liquidity and capital resources discussion is not provided in the supplied filing context. No capital allocation themes can be identified.
What to watch
Monitor the company's revenue growth trajectory in the next filing, as it has been a key metric with consistent increases.